Nature Reviews Drug Discovery contents May 2016 Volume 15 Number 5 pp 293-367

If you are unable to see the message below, click here to view.

Advertisement
Rethinking the Role of the CRO in Drug Discovery Now more than ever, modern discovery programs rely on a diverse collection of specialized techniques and dedicated collaborators with common goals. In a recent interview, head of Discovery, Dr. Emily Hickey, shared how Charles River is prepared to navigate the demands of this ever-changing landscape, and meet the challenges that may arise.
TABLE OF CONTENTS
May 2016 Volume 15 Number 5		Advertisement
Impact Factor 41.908 *	In this issue Comment News and Analysis Research Highlights Perspectives Reviews Also this month  Featured article: Coronaviruses & drug discovery and therapeutic options Alimuddin Zumla, Jasper F. W. Chan, Esam I. Azhar, David S. C. Hui & Kwok-Yung Yuen	Need grams of recombinant Antibody fast? Choose our advanced CHO GS technology and get gram-level Ab expression in 8 weeks  Learn More
Subscribe   Facebook   RSS   Recommend to library   Twitter
Advertisement
BIOPHARMA DEALMAKERS Company Profiles and Partnering Opportunities
Advertisement
nature.com webcasts Nature Publishing Group presents a custom webcast on Advances in neuroscience: New methods for correlating structure and function Thursday May 5, 2016 8AM PDT, 10AM CDT, 11AM EDT, 4PM BST, 5PM CEST  Register for the webcast and live Q&A session Sponsored by: Leica Microsystems
Advertisement
THE GENOMICS OF COMMON DISEASES 2016  Presented by Nature Genetics in association with the Wellcome Trust September 25-28, 2016 Renaissance Baltimore Harborplace Hotel | Baltimore, MD, USA REGISTER NOW!
Comment: Evolution of frameworks for expediting access to new drugs in Japan Yasuhiro Fujiwara p293 | doi:10.1038/nrd.2016.68 Japanese clinical research and regulatory frameworks have evolved considerably in the past two decades to reduce the delay in the introduction of new drugs in Japan compared with other major markets. However, recently introduced changes related to access to unapproved drugs might have the opposite effect and might not benefit all patients. Abstract | Full Text | PDF | Supplementary information
NEWS AND ANALYSIS		Top
Drug developers delve into the cell's trash-disposal machinery Kelly Rae Chi p295 | doi:10.1038/nrd.2016.86 Can drug developers move beyond the success of proteasome inhibitors to better harness the therapeutic potential of the ubiquitin-proteasome system? PDF
NIH tackles clinical trial shortcomings Asher Mullard p297 | doi:10.1038/nrd.2016.87 The NIH is developing new tools, and overhauling its clinical trial funding system, to improve the stewardship of NIH-funded clinical trials. PDF
NEWS IN BRIEF FDA rejects first cognitive claim for antidepressant Asher Mullard p299 | doi:10.1038/nrd.2016.92 PDF
EMA greenlights second gene therapy Asher Mullard p299 | doi:10.1038/nrd.2016.93 PDF
US drug spending hits $425 billion Asher Mullard p299 | doi:10.1038/nrd.2016.94 PDF
BIOBUSINESS BRIEFS Deal watch: Bristol-Myers Squibb acquires potential keys to treating rheumatoid arthritis Megan Cully p301 | doi:10.1038/nrd.2016.84 PDF
AN AUDIENCE WITH Stevin Zorn p302 | doi:10.1038/nrd.2016.70 Stevin Zorn, executive scientist in residence at Lundbeck Research USA, discusses the growing interest in how inflammation might drive Alzheimer disease and mood disorders. PDF
FROM THE ANALYST'S COUCH Rheumatoid arthritis: current and future trends Kritika Chaudhari, Salman Rizvi & Basharut A. Syed p305 | doi:10.1038/nrd.2016.21 This article analyses the market for rheumatoid arthritis therapies, which is growing rapidly, with a range of new disease-modifying drugs poised to enter in the next few years. PDF
RESEARCH HIGHLIGHTS Top Viral infection: Therapeutic post-infection options for Ebola virus treatment set to broaden p307 | doi:10.1038/nrd.2016.82 PDF Infectious disease: Combination therapy combats MRSA p308 | doi:10.1038/nrd.2016.71 PDF Cardiovascular disease: Dissolving cholesterol to unclog arteries p308 | doi:10.1038/nrd.2016.90 PDF Neurodegeneration: HIF-PHD inhibition ameliorates damage after brain haemorrhage p309 | doi:10.1038/nrd.2016.72 PDF Spinal cord injury: Clamping down on calpains to treat injury-induced spasticity p310 | doi:10.1038/nrd.2016.83 PDF IN BRIEF Breast cancer: Inhibiting fatty acid oxidation blocks tumour growth | Metabolic disease: Beige cells secrete thermogenic factor | Ovarian cancer: Cyclic peptide inhibits metastases | Anticancer drugs: Tumour-specific angiogenesis inhibition PDF Drug Discovery JOBS of the week More Science jobs from Drug Discovery EVENT Partnerships Opportunities in Drug Delivery 27.10.16 Boston, USA More science events from
Advertisement
Droplet Digital™ PCR (ddPCR™) is leading the way  Droplet Digital PCR has led to more publications and discoveries than any other digital PCR platform - over 400 studies have taken advantage of ddPCR technology. Find out how
PERSPECTIVES		Top
OPINION Epithelial-mesenchymal transition: a new target in anticancer drug discovery Fabrizio Marcucci, Giorgio Stassi & Ruggero De Maria p311 | doi:10.1038/nrd.2015.13 The conversion of cells with an epithelial phenotype into cells with a mesenchymal phenotype — epithelial-mesenchymal transition — has a key role in tumour progression and is therefore becoming a promising anticancer target. This article discusses the screening and classification of compounds that affect epithelial-mesenchymal transition, highlights some compounds of particular interest and discusses issues related to their clinical application. Abstract | Full Text | PDF
Advertisement
Open for Submissions  npj Precision Oncology is a new open access, online-only, peer-reviewed journal committed to publishing cutting-edge scientific research in all aspects of precision oncology from basic science to translational applications, to clinical medicine. The journal is part of the Nature Partner Journals series and published in partnership with The Hormel Institute, University of Minnesota.  Explore the benefits of submitting your manuscript>>
REVIEWS		Top
Coronaviruses — drug discovery and therapeutic options Alimuddin Zumla, Jasper F. W. Chan, Esam I. Azhar, David S. C. Hui & Kwok-Yung Yuen p327 | doi:10.1038/nrd.2015.37 Severe acute respiratory syndrome (SARS) and Middle East respiratory syndrome (MERS), which are caused by coronaviruses, have attracted substantial attention owing to their high mortality rates and potential to cause epidemics. Yuen and colleagues discuss progress with treatment options for these syndromes, including virus- and host-targeted drugs, and the challenges that need to be overcome in their further development. Abstract | Full Text | PDF | Supplementary information
Regulated necrosis: disease relevance and therapeutic opportunities Marcus Conrad, José Pedro Friedmann Angeli, Peter Vandenabeele & Brent R. Stockwell p348 | doi:10.1038/nrd.2015.6 Forms of cell death besides apoptosis and necrosis are becoming increasingly well understood, and are relevant to many disease contexts. Here, Conrad et al. describe the mechanisms underlying regulated forms of necrosis — including necroptosis, ferroptosis, parthanatos and cyclophilin D-mediated necrosis — and efforts to induce or prevent them in disease. Abstract | Full Text | PDF
Erratum: European Lead Factory hits its stride Katie Kingwell p367 | doi:10.1038/nrd.2016.73 Full Text | PDF
Advertisement
nature.com webcasts Nature Publishing Group presents an editorial webcast on: Cancer immunotherapy Join us as four experts explain their roles in this exciting field and take part in a live discussion on the future of cancer immunotherapy. Tuesday 24th May 2016 at 8AM PDT, 11AM EDT, 4PM BST, 5PM CEST Register free online: Produced with support from: Lonza Bioscience Solutions
Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events

*2013 Journal Citation Report (Thomson Reuters, 2014)

You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department For print subscription enquiries, please contact our subscription department For other enquiries, please contact our feedback department Nature Publishing Group | One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Nature Publishing Group's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at Brunel Road, Houndmills, Basingstoke, Hampshire RG21 6XS. © 2016 Nature Publishing Group, a division of Macmillan Publishers Limited. All Rights Reserved.